Swiss League Against Epilepsy
The Epilepsy League is inviting applications for three awards to be presented in 2023.
The Alfred Hauptmann Award for the best experimental or clinical research now comes with prize money of €20,000 – previously the amount was €10,000. Half the prize money will be awarded to the author of a basic research document that has been published, while the other half will be awarded in the field of clinical research. This has been made possible thanks to new sponsors: the award is now supported by the companies UCB-Pharma, Desitin Pharma, Arvelle/Angelini Pharma and GW/Jazz Pharmaceuticals.
The Alfred Hauptmann Award is presented every two years by the German and Austrian epileptology associations together with the Swiss Epilepsy League. It is named after the German neurologist Alfred Hauptmann, who had to emigrate from Germany in 1933.
More about the award: https://www.epi.ch/hauptmann-award
A second award scheduled for next year is the Prize for Best Dissertation, which goes to the best master’s or doctoral thesis from a Swiss university in the field of epileptology and carries prize money of CHF 1,000. Applications are welcome from all disciplines. So as well as medical students, anyone writing a thesis in the field of epilepsy is invited to apply, for example students of psychology or pharmacology.
Finally, applications are also open for the 2023 Research Recognition Award, presented by the Swiss League Against Epilepsy with prize money of CHF 25,000. It is awarded annually to researchers working in Switzerland as start-up funding for research projects. Preference is given to those who are researching causes of and therapies for epilepsies.
Applications for all three awards are open until 31 December 2022.
Call for Applications
The Swiss League Against Epilepsy (Epilepsy League) is a specialist organisation which works throughout Switzerland and at the same time represents the Swiss Chapter of the International League Against Epilepsy (ILAE).
The Epilepsy League researches, helps and informs. Its goal is to provide a lasting improvement to the everyday life of those affected by epilepsy and their situation in society.